7SV7

The complex of phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with ATP/Mg and Tezacaftor (VX-661)

7SV7 の概要

• エントリーDOI: 10.2210/pdb7sv7/pdb
• EMDBエントリー: 25445
• 分子名称: Cystic fibrosis transmembrane conductance regulator, Tezacaftor, MAGNESIUM ION, ... (10 entities in total)
• 機能のキーワード: abc transporter, ion channel, folding correction, atp-binding protein, membrane protein
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 173532.75

構造登録者

Fiedorczuk, K.,Chen, J. (登録日: 2021-11-18, 公開日: 2022-01-12, 最終更新日: 2025-05-21)

主引用文献

Fiedorczuk, K.,Chen, J.
Mechanism of CFTR correction by type I folding correctors.
Cell, 185:158-168.e11, 2022

PubMed Abstract: Small molecule chaperones have been exploited as therapeutics for the hundreds of diseases caused by protein misfolding. The most successful examples are the CFTR correctors, which transformed cystic fibrosis therapy. These molecules revert folding defects of the ΔF508 mutant and are widely used to treat patients. To investigate the molecular mechanism of their action, we determined cryo-electron microscopy structures of CFTR in complex with the FDA-approved correctors lumacaftor or tezacaftor. Both drugs insert into a hydrophobic pocket in the first transmembrane domain (TMD1), linking together four helices that are thermodynamically unstable. Mutating residues at the binding site rendered ΔF508-CFTR insensitive to lumacaftor and tezacaftor, underscoring the functional significance of the structural discovery. These results support a mechanism in which the correctors stabilize TMD1 at an early stage of biogenesis, prevent its premature degradation, and thereby allosterically rescuing many disease-causing mutations.

PubMed: 34995514
DOI: 10.1016/j.cell.2021.12.009

実験手法

ELECTRON MICROSCOPY (3.8 Å)